RT Journal Article
SR Electronic
T1 Association between mobility, non-pharmaceutical interventions, and COVID-19 transmission in Ghana: a modelling study using mobile phone data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.01.21265660
DO 10.1101/2021.11.01.21265660
A1 Gibbs, Hamish
A1 Liu, Yang
A1 Abbott, Sam
A1 Baffoe-Nyarko, Isaac
A1 Laryea, Dennis O.
A1 Akyereko, Ernest
A1 Kuma-Aboagye, Patrick
A1 Asante, Ivy
A1 Mitjà, Oriol
A1 ,
A1 Ampofo, William
A1 Asiedu-Bekoe, Franklin
A1 Marks, Michael
A1 Eggo, Rosalind M.
YR 2021
UL http://medrxiv.org/content/early/2021/11/17/2021.11.01.21265660.abstract
AB Background Governments around the world have implemented non-pharmaceutical interventions to limit the transmission of COVID-19. While lockdowns and physical distancing have proven effective for reducing COVID-19 transmission, there is still limited understanding of how NPI measures are reflected in indicators of human mobility. Further, there is a lack of understanding about how findings from high-income settings correspond to low and middle-income contexts.Methods In this study, we assess the relationship between indicators of human mobility, NPIs, and estimates of Rt, a real-time measure of the intensity of COVID-19 transmission. We construct a multilevel generalised linear mixed model, combining local disease surveillance data from subnational districts of Ghana with the timing of NPIs and indicators of human mobility from Google and Vodafone Ghana.Findings We observe a relationship between reductions in human mobility and decreases in Rt during the early stages of the COVID-19 epidemic in Ghana. We find that the strength of this relationship varies through time, decreasing after the most stringent period of interventions in the early epidemic.Interpretation Our findings demonstrate how the association of NPI and mobility indicators with COVID-19 transmission may vary through time. Further, we demonstrate the utility of combining local disease surveillance data with large scale human mobility data to augment existing surveillance capacity and monitor the impact of NPI policies.Evidence before this study We searched PubMed and preprint archives for articles published in English that contained information about the COVID-19 pandemic published up to Nov 1, 2021, using the search terms “coronavirus”, “CoV”, “COVID-19”, “mobility”, “movement”, and “flow”. The data thus far suggests that NPI measures including physical distancing, reduction of travel, and use of personal protective equipment have been demonstrated to reduce COVID-19 transmission. Much of the existing research focuses on comparisons of NPI stringency with COVID-19 transmission among different high-income countries, or on high-income countries, leaving critical questions about the applicability of these findings to low- and middle-income settings.Added value of this study We used a detailed COVID-19 surveillance dataset from Ghana, and unique high resolution spatial data on human mobility from Vodafone Ghana as well as Google smartphone GPS location data. We show how human mobility and NPI stringency were associated with changes in the effective reproduction number (Rt). We further demonstrate how this association was strongest in the early COVID-19 outbreak in Ghana, decreasing after the relaxation of national restrictions.Implications of all the available evidence The change in association between human mobility, NPI stringency, and Rt may reflect a “decoupling” of NPI stringency and human mobility from disease transmission in Ghana as the COVID-19 epidemic progressed. This finding provides public health decision makers with important insights for the understanding of the utility of mobility data for predicting the spread of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors. This research was partly funded by the Bill & Melinda Gates Foundation (INV-003174: YL). EDCTP2 (RIA2020EF-2983-CSIGN: HPG, OM, RME, MM). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: YL). HDR UK (MR/S003975/1: RME). This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (16/137/109: YL; NIHR200908: RME). UK DHSC/UK Aid/NIHR (PR-OD-1017-20001: HPG). UK MRC (MC_PC_19065: RME, YL). Wellcome Trust (210758/Z/18/Z: SA). The following funding sources are acknowledged as providing funding for the working group authors. BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: JYL, KP, MJ; INV-016832: SRP; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1139859: BJQ; OPP1183986: ESN; OPP1191821: KO'R, MA). BMGF (INV-016832; OPP1157270: KA). CADDE MR/S0195/1 & FAPESP 18/14389-0 (PM). DTRA (HDTRA1-18-1-0051: JWR). Elrha R2HC/UK FCDO/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757699: JCE, MQ, RMGJH). ERC (SG 757688: CJVA, KEA). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: AG, KLM, KP, MJ, PK, RCB, WJE). FCDO/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP, KvZ). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: CIJ, TJ). HPRU (NIHR200908: NIB). Innovation Fund (01VSF18015: FK). MRC (MR/N013638/1: EF, NRW; MR/V027956/1: WW). Nakajima Foundation (AE). NIHR (16/136/46: BJQ; 16/137/109: BJQ, CD, FYS, MJ; 1R01AI141534-01A1: DH; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ; NIHR200908: AJK, LACC; NIHR200929: CVM, FGS, MJ, NGD; PR-OD-1017-20002: AR, WJE). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). Singapore Ministry of Health (RP). UK MRC (LID DTP MR/N013638/1: GRGL, QJL; MC_PC_19065: NGD, SC, TJ, WJE; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). UKRI (MR/V028456/1: YJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JDM, JH, KS, SFunk, SRM; 221303/Z/20/Z: MK; UNS110424: FK). No funding (AKD, AMF, AS, DCT, JW, SH, YWDC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the LSHTM Research Ethics Committee (Ref: 22477) and the Noguchi Memorial Institute of Medical Research (Ref: 048/20-21).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study included individual Line List data shared with authors by the Ghana Health Service. Use of this data was approved by the LSHTM Research Committee (Ref: 22477) and the Noguchi Memorial Institute of Medical Research (Ref: 048/20-21). Vodafone mobility data used in this study is proprietary data shared by Vodafone Ghana in partnership with the Flowminder Foundation and Ghana Statistical Service. This mobility data is available to researchers by application. Google mobility data used in this study is available in the public domain. Downloads of this data can be found in the references. Code used in this study is available from: https://github.com/hamishgibbs/ghana_rt_npi_mobility. https://github.com/hamishgibbs/ghana_rt_npi_mobility